Special Issue "Immune-Related Adverse Effects of Checkpoint Inhibitors in Cancer Patients"
Deadline for manuscript submissions: closed (31 October 2023) | Viewed by 4642
The development of immune checkpoint inhibitors (ICIs) has significantly altered the field of oncology by achieving durable anti-tumor responses in a number of advanced malignancies with previously poor prognoses. Currently, up to 50% of all cancer patients can potentially benefit from a treatment with ICIs. ICIs are monoclonal antibodies that block inhibitory ligand–receptor interactions, essential for both immunological homeostasis and self-tolerance, in order to enhance the activity of a patient’s immune system to fight cancer. In 2011, ipilimumab (Yervoy®), an inhibitor of the T-lymphocyte-associated antigen-4 (CTLA-4), was the first ICI to gain approval from the United States Food and Drug Administration (FDA). In the following years, other ICIs have also become clinically available, namely inhibitors of programmed cell death protein-1 (PD-1; nivolumab, pembrolizumab, cemiplimab, dostarlimab) and its ligand, programmed cell death ligand-1 (PD-L1; atezolizumab, avelumab, durvalumab). In 2022, a second CTLA-4 also gained the FDAs approval, in combination with durvalumab, i.e., tremelimumab. As opposed to the conventional anti-cancer therapies, characterized by acute onset emetic and myelosuppressive effects, ICIs exhibit a favorable side effect profile. Nevertheless, their increased use over the last few years has led to the discovery of a distinct set of adverse effects, i.e., immune-related adverse events (irAEs). irAEs have gained significant interest over the past decade. Although initially research focused on fatal and severe adverse events, the increasing use of ICIs in the treatment of both the advanced and early stages of various malignancies has resulted in a substantial increase in the incidence of both acute and chronic irAEs. Approximately 50% of the patients who receive ICI treatment will experience some kind of irAE. This Special Issue will focus on a wide range of irAEs affecting different organs during ICI treatment.
Prof. Dr. Christof Vulsteke
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceuticals is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- checkpoint inhibitors
- immune-related adverse events